Pharsight

Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Inveltys is owned by Alcon Labs Inc.

Inveltys contains Loteprednol Etabonate.

Inveltys has a total of 1 drug patent out of which 0 drug patents have expired.

Inveltys was authorised for market use on 22 August, 2018.

Inveltys is available in suspension/drops;ophthalmic dosage forms.

The generics of Inveltys are possible to be released after 03 May, 2033.

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11219597 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10864219 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10646437 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Inveltys is owned by Kala Pharms Inc.

Inveltys contains Loteprednol Etabonate.

Inveltys has a total of 10 drug patents out of which 0 drug patents have expired.

Inveltys was authorised for market use on 22 August, 2018.

Inveltys is available in suspension/drops;ophthalmic dosage forms.

Inveltys can be used as a method for delivering a composition to a mucus membrane, a method for delivering a pharmaceutical agent across a mucosal barrier, a method for treating inflammation and/or other disorders in an eye of a patient, a method for treating ocular inflammation, a method of reducing post-surgical pain following ocular surgery; a method of treating postoperative inflammation following ocular surgery.

The generics of Inveltys are possible to be released after 03 May, 2033.

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A ...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic